Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MS, MRI, and the 2010 McDonald criteria: a Canadian expert commentary.
Selchen D, Bhan V, Blevins G, Devonshire V, Duquette P, Grand'Maison F, Kremenchutzky M, Lapierre Y, Li D, von Riedemann SJ, Freedman M. Selchen D, et al. Neurology. 2012 Dec 4;79(23 Suppl 2):S1-15. doi: 10.1212/WNL.0b013e318277d144. Neurology. 2012. PMID: 23212280
Treatment optimization in multiple sclerosis.
Freedman MS, Patry DG, Grand'Maison F, Myles ML, Paty DW, Selchen DH; Canadian MS Working Group. Freedman MS, et al. Can J Neurol Sci. 2004 May;31(2):157-68. doi: 10.1017/s0317167100053804. Can J Neurol Sci. 2004. PMID: 15198439 Review.
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group; O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G. O'Connor P, et al. Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Lancet Neurol. 2009. PMID: 19729344 Clinical Trial.
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Radue EW, et al. Arch Neurol. 2012 Oct;69(10):1259-69. doi: 10.1001/archneurol.2012.1051. Arch Neurol. 2012. PMID: 22751847 Clinical Trial.
Treatment optimization in MS: Canadian MS Working Group updated recommendations.
Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, Morgenthau D, Lapierre Y; Canadian Multiple Sclerosis Working Group. Freedman MS, et al. Among authors: selchen d. Can J Neurol Sci. 2013 May;40(3):307-23. doi: 10.1017/s0317167100014244. Can J Neurol Sci. 2013. PMID: 23603165 Review.
Anti-JC Virus Antibody Prevalence in Canadian MS Patients.
Bhan V, Lapierre Y, Freedman MS, Duquette P, Selchen D, Migounov V, Walt L, Zhang A. Bhan V, et al. Among authors: selchen d. Can J Neurol Sci. 2014 Nov;41(6):748-52. doi: 10.1017/cjn.2014.32. Epub 2014 Nov 4. Can J Neurol Sci. 2014. PMID: 25377521
Everything Old is New Again.
Florendo-Cumbermack A, Selchen D, Morrow SA, Sharma M, Steven D, Ang LC, Casserly C, Burneo J, Kremenchutzky M, Hammond R. Florendo-Cumbermack A, et al. Among authors: selchen d. Can J Neurol Sci. 2016 Jan;43(1):213-8. doi: 10.1017/cjn.2015.309. Can J Neurol Sci. 2016. PMID: 27182570 No abstract available.
92 results